Celcuity Inc CELC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026
-
Celcuity Appoints David Gryska To Its Board Of Directors
-
Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
-
Celcuity To Participate in Upcoming Investor Conferences
-
Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
-
Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC
-
Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call
Trading Information
- Previous Close Price
- $61.56
- Day Range
- $62.07–66.93
- 52-Week Range
- $53.59–150.82
- Bid/Ask
- $64.84 / $65.05
- Shares Outstanding
- 48.93M
- Market Cap
- $3.19B
- Volume/Avg
- 1M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 155
- Website
- https://www.celcuity.com
Valuation
|
Metric
|
CELC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CELC
|
|---|---|
Quick Ratio | 8.68 |
Current Ratio | 8.93 |
Interest Coverage | −9.89 |
Quick Ratio
CELC
Profitability
|
Metric
|
CELC
|
|---|---|
Return on Assets (Normalized) | −38.30% |
Return on Equity (Normalized) | −299.21% |
Return on Invested Capital (Normalized) | −41.18% |
Return on Assets
CELC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|MLRVzmz | LOCK|<%#%N | $133B | |||
| Moderna Inc
MRNA
| LOCK|Hlp#j> | LOCK|g& | $98B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|vlh!P# | LOCK|C#&H | $83B | |||
| argenx SE ADR
ARGX
| LOCK|$!@kJ>d | LOCK|#ph | $56B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?pZ>Ws | LOCK|CN? | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|#v?>l@ | LOCK|%QGL | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Zn@gbSx | LOCK|yF%j | $28B | |||
| Incyte Corp
INCY
| LOCK|G%!$p> | LOCK|<## | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|n$#!$!g | LOCK|RG | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|^@>d!%g | LOCK|>v | $14B |
United States